Scudla V, Indrák K
Neoplasma. 1985;32(4):481-93.
A group of 193 multiple myeloma (MM) patients consisting of cases treated only symptomatically (1959-63) or by nonsystematic monotherapy with Cyclophosphamide or Melphalan (1963-76) and of a subgroup given systematic polychemotherapy and intensive supportive treatment (1976-84) were evaluated for the practical applicability and prognostic relevance of three staging systems. The clinical staging system of Durie and Salmon and the quantitative system of Salmon and Wampler have proved in both subgroups of various periods and with different therapeutic approaches to be well applicable in the clinic allowing the patients to be divided into three prognostically different groups according to the size of the tumor mass. Merlini, Waldenström and Jayakar's staging system has likewise shown relationship to prognosis though the patients could be divided only into two prognostically different groups. It is evident that a deeper knowledge of MM requires nowadays a more comprehensive, complex and prognostically more relevant classification system.
对一组193例多发性骨髓瘤（MM）患者进行了评估，这些患者包括仅接受对症治疗的病例（1959 - 1963年）、接受环磷酰胺或美法仑非系统性单一疗法治疗的病例（1963 - 1976年）以及接受系统性多药化疗和强化支持治疗的亚组（1976 - 1984年），以评估三种分期系统的实际适用性和预后相关性。Durie和Salmon的临床分期系统以及Salmon和Wampler的定量系统在不同时期的两个亚组中，以及采用不同治疗方法时，均已证明在临床上具有良好的适用性，能够根据肿瘤肿块大小将患者分为预后不同的三组。Merlini、Waldenström和Jayakar的分期系统同样显示出与预后的关系，尽管患者只能分为预后不同的两组。显然，如今要更深入地了解多发性骨髓瘤，需要一个更全面、复杂且预后相关性更强的分类系统。
